These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36265539)

  • 1. Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells.
    Barbera S; Raucci L; Tassone G; Tinti L; Prischi F; Santucci A; Mongiat M; Tosi GM; Galvagni F; Dimberg A; Pozzi C; Orlandini M
    Int J Biol Macromol; 2023 Jan; 224():453-464. PubMed ID: 36265539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
    Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
    Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.
    Tosi GM; Neri G; Barbera S; Mundo L; Parolini B; Lazzi S; Lugano R; Poletto E; Leoncini L; Pertile G; Mongiat M; Dimberg A; Galvagni F; Orlandini M
    Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):30. PubMed ID: 32697305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.
    Barbera S; Nardi F; Elia I; Realini G; Lugano R; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
    Cell Commun Signal; 2019 May; 17(1):55. PubMed ID: 31138217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
    Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
    Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
    Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
    J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases.
    Barbera S; Lugano R; Pedalina A; Mongiat M; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
    Matrix Biol; 2021 May; 99():1-17. PubMed ID: 34062268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
    Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A
    Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells.
    Barbera S; Raucci L; Lugano R; Tosi GM; Dimberg A; Santucci A; Galvagni F; Orlandini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.
    Nativel B; Ramin-Mangata S; Mevizou R; Figuester A; Andries J; Iwema T; Ikewaki N; Gasque P; Viranaïcken W
    Immunology; 2019 Oct; 158(2):85-93. PubMed ID: 31335975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.
    Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M
    Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD93 promotes acute myeloid leukemia development and is a potential therapeutic target.
    Jia J; Liu B; Wang D; Wang X; Song L; Ren Y; Guo Z; Ma K; Cui C
    Exp Cell Res; 2022 Nov; 420(2):113361. PubMed ID: 36152731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93.
    Cicaloni V; Karmakar M; Frusciante L; Pettini F; Visibelli A; Orlandini M; Galvagni F; Mongiat M; Silk M; Nardi F; Ascher D; Santucci A; Spiga O
    Front Bioinform; 2022; 2():891553. PubMed ID: 36353214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
    Khan KA; McMurray JL; Mohammed F; Bicknell R
    FEBS J; 2019 Sep; 286(17):3299-3332. PubMed ID: 31287944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.
    Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL
    PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD93 as a Potential Target in Neovascular Age-Related Macular Degeneration.
    Tosi GM; Caldi E; Parolini B; Toti P; Neri G; Nardi F; Traversi C; Cevenini G; Marigliani D; Nuti E; Bacci T; Galvagni F; Orlandini M
    J Cell Physiol; 2017 Jul; 232(7):1767-1773. PubMed ID: 27859225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD93 maintains endothelial barrier function and limits metastatic dissemination.
    Vemuri K; de Alves Pereira B; Fuenzalida P; Subashi Y; Barbera S; van Hooren L; Hedlund M; Pontén F; Lindskog C; Olsson AK; Lugano R; Dimberg A
    JCI Insight; 2024 Mar; 9(7):. PubMed ID: 38441970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insight into CD93 recognition by IGFBP7.
    Xu Y; Sun Y; Zhu Y; Song G
    Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.
    Orlandini M; Galvagni F; Bardelli M; Rocchigiani M; Lentucci C; Anselmi F; Zippo A; Bini L; Oliviero S
    Oncotarget; 2014 May; 5(9):2750-60. PubMed ID: 24809468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD93 negatively regulates astrogenesis in response to MMRN2 through the transcriptional repressor ZFP503 in the developing brain.
    Liang Q; Su L; Zhang D; Jiao J
    Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9413-9422. PubMed ID: 32291340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.